Form 4: BioLife Solutions Director Sells $108K in Stock

BioLife Solutions Director Amy DuRoss sold 4,000 shares of common stock for $108,000 through a pre-arranged trading plan.

Summary

• Amy DuRoss, a Director at BioLife Solutions Inc. (BLFS), reported the sale of 4,000 shares of common stock.
• The transactions occurred on November 25, 2025, and November 26, 2025.
• On November 25, 2025, 2,000 shares were sold at a price of $27.00 per share.
• On November 26, 2025, an additional 2,000 shares were sold at a price of $27.00 per share.
• The total value of the shares disposed of was $108,000 (4,000 shares * $27.00/share).
• Following these transactions, Amy DuRoss beneficially owns 20,687 shares of common stock directly.
• The transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase or sale of equity securities.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can be perceived negatively, the execution under a Rule 10b5-1 plan suggests a pre-planned, non-opportunistic sale, which mitigates concerns about its implications for the company's immediate prospects.

Positives

• The sales were executed under a Rule 10b5-1 trading plan, which indicates the transactions were pre-scheduled and not based on new, material non-public information, mitigating concerns about opportunistic insider selling.

Negatives

• Insider selling, even if planned, reduces the overall insider ownership percentage, which some investors may view as a slight negative signal regarding management's conviction in the company's future prospects.

Industry Context

This filing is a routine disclosure of an insider stock transaction and does not provide specific industry context or trends. It reflects an individual director's portfolio management.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a minor negative, but the 10b5-1 plan reduces concerns about the timing or underlying reasons for the sale.

Key Dates

Recommendation

The insider sale by a director, while reducing insider ownership, was conducted under a Rule 10b5-1 trading plan. This indicates a pre-scheduled transaction rather than one based on new, material non-public information. As such, this event alone does not provide a strong signal for a buy or sell recommendation and is best viewed as a neutral event for investment decisions, warranting a 'hold' position.

Keywords

BioLife Solutions, BLFS, Insider Sale, Form 4, Amy DuRoss, Director Sale, Stock Transaction, 10b5-1 Plan